Fecal Lactoferrin for Assessment of Inflammatory Bowel Disease Activity: A Systematic Review and Meta-Analysis.

ibdwatch

Fecal Lactoferrin for Assessment of Inflammatory Bowel Disease Activity: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2019 Apr 15;: Authors: Dai C, Jiang M, Sun MJ, Cao Q Abstract OBJECTIVE: Persistent disease activity is associated with a poor prognosis in inflammatory bowel disease (IBD) patients. Therefore, monitoring of IBD activity can avoid the poor prognosis. Serum biomarkers reflect a summation of systemic host responses rather than being specific for intestinal inflammation. And endoscopic monitoring is invasive, costly, and time consuming. The objective of our study was to perform a…

Read More

Endoscopic Resections in Inflammatory Bowel Disease: A Multicentre European Outcomes Study.

ibdwatch

Endoscopic Resections in Inflammatory Bowel Disease: A Multicentre European Outcomes Study. J Crohns Colitis. 2019 Apr 17;: Authors: Al-Kandari A, Thayalasekaran S, Bhandari M, Przybysz A, Bugajski M, Bassett P, Kandiah K, Subramaniam S, Galtieri P, Maselli R, Spychalski M, Hayee B, Haji A, Repici A, Kaminski M, Bhandari P Abstract BACKGROUND: Inflammatory bowel disease is associated with an increased risk of colorectal cancer, with estimates ranging from 2-18%, depending on the duration of colitis. The management of neoplasia in colitis remains controversial. Current guidelines recommend endoscopic resection if the…

Read More

Non-invasive Multi-modal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn’s Disease.

ibdwatch

Non-invasive Multi-modal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn’s Disease. Clin Gastroenterol Hepatol. 2019 Apr 14;: Authors: Allocca M, Fiorino G, Bonifacio C, Peyrin-Biroulet L, Danese S Abstract Fibrotic strictures occur in 30% of patients with Crohn’s disease (CD). However, there are no therapeutic agents that prevent or reverse fibrotic strictures. Strictures are treated by endoscopic dilatation procedures and surgical procedures, but there are high rates of recurrence. Two anti-fibrotic agents (nintedanib and pirfenidone) were recently approved for the treatment of idiopathic pulmonary fibrosis and inhibitors…

Read More

A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong District of Seoul, Korea in 1986-2015.

ibdwatch

Related Articles A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong District of Seoul, Korea in 1986-2015. J Crohns Colitis. 2019 Apr 16;: Authors: Park SH, Kim YJ, Rhee KH, Kim YH, Hong SN, Kim KH, Seo SI, Cha JM, Park SY, Jeong SK, Lee JH, Park H, Kim JS, Im JP, Yoon H, Kim SH, Jang J, Kim JH, Suh SO, Kim YK, Ye BD, Yang SK, Songpa-Kangdong Inflammatory Bowel Disease (SK-IBD) Study Group Abstract BACKGROUND AND AIMS: Although the incidence of inflammatory bowel…

Read More

Low Golimumab Trough Levels at Week 6 are Associated with Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study.

ibdwatch

Related Articles Low Golimumab Trough Levels at Week 6 are Associated with Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study. J Crohns Colitis. 2019 Apr 16;: Authors: Magro F, Lopes S, Silva M, Coelho R, Portela F, Branquinho D, Correia L, Fernandes S, Cravo M, Caldeira P, Tavares Sousa H, Patita M, Lago P, Ramos J, Afonso J, Redondo I, Machado P, Cornillie F, Lopes J, Carneiro F, portuguese IBD group (GEDII) Abstract BACKGROUND AND AIMS: Golimumab has an established…

Read More

Letter to the Editor: Patients With Inflammatory Bowel Disease Demonstrate an Inherent Lack of Psychopathology.

ibdwatch

Related Articles Letter to the Editor: Patients With Inflammatory Bowel Disease Demonstrate an Inherent Lack of Psychopathology. Inflamm Bowel Dis. 2019 Apr 16;: Authors: Taft TH, Quinton S, Tomasino K, Craven M, Guadagnoli L, Bedell A, Hanauer S PMID: 30989208 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30989208?dopt=Abstract

Read More

Increased Healthcare Utilization by Patients With Inflammatory Bowel Disease Covered by Medicaid at a Tertiary Care Center.

ibdwatch

Related Articles Increased Healthcare Utilization by Patients With Inflammatory Bowel Disease Covered by Medicaid at a Tertiary Care Center. Inflamm Bowel Dis. 2019 Apr 16;: Authors: Axelrad JE, Sharma R, Laszkowska M, Packey C, Rosenberg R, Lebwohl B Abstract BACKGROUND: Low socioeconomic status has been linked with numerous poor health outcomes, but data are limited regarding the impact of insurance status on inflammatory bowel disease (IBD) outcomes. We aimed to characterize utilization of healthcare resources by IBD patients based on health insurance status, using Medicaid enrollment as a proxy for…

Read More

Informed Consent in IBD Trials: Where We Are and Where We Need to Go.

ibdwatch

Related Articles Informed Consent in IBD Trials: Where We Are and Where We Need to Go. Inflamm Bowel Dis. 2019 Apr 16;: Authors: Kurin M, Katz J, Kodish E, Lashner B Abstract Patient enrollment is increasingly recognized as a major limiting factor to inflammatory bowel disease (IBD) clinical trial completion. Many IBD trials will fail to enroll enough patients to adequately power their study. This has led to a renewed multifaceted effort to encourage more patients to enroll in clinical trials. Although this is of clear importance, it is also…

Read More

Long-term clinical effectiveness of ustekinumab in patients with Crohn’s disease who failed biological therapies: a national cohort study.

ibdwatch

Related Articles Long-term clinical effectiveness of ustekinumab in patients with Crohn’s disease who failed biological therapies: a national cohort study. J Crohns Colitis. 2019 Apr 16;: Authors: Liefferinckx C, Verstockt B, Gils A, Noman M, Van Kemseke C, Macken E, De Vos M, Van Moerkercke W, Rahier JF, Bossuyt P, Dutré J, Humblet E, Staessen D, Peeters H, Van Hootegem P, Louis E, Franchimont D, Baert F, Vermeire S, Belgian Inflammatory Bowel Disease Research and Development Group (BIRD group) Abstract BACKGROUND: Ustekinumab (UST) was recently approved in Europe for the…

Read More
<< Go Back